NCT04504331 2026-02-12
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Stanford University
Phase 1 Terminated
Clinical Trials
4 trialsNCT04424966 2025-10-24
Infigratinib in Recurrent High-Grade Glioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Terminated
NCT04228042 2025-01-01
Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02706691 2019-04-16
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
University of Chicago
Phase 2 Terminated